908 Devices (MASS)
(Delayed Data from NSDQ)
$5.32 USD
-0.02 (-0.37%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.33 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MASS 5.32 -0.02(-0.37%)
Will MASS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MASS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MASS
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MASS: What are Zacks experts saying now?
Zacks Private Portfolio Services
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Top Estimates
Other News for MASS
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
908 Devices appoints Leonhart to Board of Directors
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
908 Devices announce enhanced qualification package for XplorIR
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), 908 Devices (MASS) and Nurix Therapeutics (NRIX)